Hepatic Impairment
Conditions
Keywords
Hepatic impairment
Brief summary
This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.
Detailed description
This study evaluated the effect of mild and moderate hepatic impairment (HI) on the pharmacokinetics of ITF2357 and its metabolites, along with the safety and tolerability in this patient population. The total number of participants enrolled in the study was 24 subjects: * 8 participants with mild HI (Child-Pugh class A) * 8 participants with moderate HI (Child-Pugh class B) * 8 participants with normal hepatic function (control group) Each participant went through: * A screening period from Day (D)-28 to D-2 * One 6-day/5-night inpatient period (from D-1 evening to D5 morning) * An end-of-study evaluation to be done on D10 (±1 day).
Interventions
DRUGITF2357
ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose
Sponsors
Italfarmaco
Biotrial
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
for Participants with HI: 1. Male or female participants, between 18 and 75 years of age, inclusive. 2. Body weight between 60.0 and 110.0 kg, inclusive if male, and between 50.0 and 100.0 kg, inclusive if female, body mass index (BMI) between 18.00 and 34.99 kg/m2, inclusive. 3. Stable chronic liver disease assessed by medical history, physical examination, laboratory values. 4. Vital signs after 10 minutes resting in supine position within the following range \[or if out of range, considered not clinically significant (NCS) by the Investigator\]: 95 mmHg \< systolic blood pressure (SBP) \< 180 mmHg; 45 mmHg \< diastolic blood pressure (DBP) \< 100 mmHg; 40 bpm \< heart rate (HR) \< 100 bpm. 5. 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances were participants enrolled with corrected QT according to Fridericia (QTcF) \> 450 ms. 6. Any confirmed clinically relevant abnormal laboratory test that, on Investigator's judgment, was inconsistent with the subject's status as a patient with hepatic impairment. However, renal function assessed using the estimated glomerular filtration rate (eGFR) calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula had to be strictly above 60 mL/min/1.73m². 7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration. 8. Female participants of non-childbearing potential, defined as one of the following: 1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at screening; 2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening. 9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to Clinical Trials Coordination Group \[CTCG\] recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include: 1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal; 2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable; 3. intrauterine device (IUD); 4. intrauterine hormone-releasing system (IUS); 5. bilateral tubal occlusion; 6. vasectomized partner; 7. sexual abstinence (when in line with the preferred and usual subject's lifestyle). Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception. 10. Had given written informed consent prior to any procedure related to the study. 11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research. 12. Not under any administrative or legal supervision. 13. For moderate HI cohort: Child-Pugh total score ranging from 7 to 9, inclusive. 14. For mild HI cohort: Child-Pugh total score ranging from 5 to 6, inclusive. 15. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.
Exclusion criteria
for Participants with HI: 1. Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness. 2. Hepatocarcinoma. 3. Acute hepatitis. 4. Hepatic encephalopathy grade 2, 3, and 4. 5. Blood donation within 2 months before inclusion. 6. Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 30 mmHg within 3 minutes when changed from supine to standing position. 7. Presence or history of drug hypersensitivity, or allergic disease, except seasonal rhinitis, diagnosed and treated by a physician. 8. History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion. 9. Smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking over 5 cigarettes per day from D-1 and throughout the entire institutionalization (i.e. up to D5). 10. Excessive consumption of beverages with xanthine bases (more than 4 cups or glasses per day). 11. If female, pregnancy \[defined as positive β-human choriogonadotropin (β-HCG) blood test\] or breast feeding. 12. Any significant change in chronic treatment medication within 14 days before inclusion. 13. Consumption of PgP or BCRP potent inducers or inhibitors that could impact the PK of the investigational product within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication before inclusion. Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the EOS visit is completed. 14. Any vaccination, including COVID-19 within 2 weeks before inclusion. 15. Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development. 16. Any participant in the exclusion period of a previous study according to applicable regulations. 17. Any participant who could not be contacted. 18. Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study. 19. Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab). 20. Positive results on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates) unless this result was secondary to a documented medical prescription (only for benzodiazepines and cannabinoids). 21. Positive alcohol breath test. 22. Any consumption of citrus fruits (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion. 23. Medications that prolong the QTc interval (refer to the list provided in Section 12 of Appendix 16.1.1) within 14 days before inclusion or within 7 times the elimination half-life before inclusion. Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the last ECG at EOS is completed. 24. Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death. Inclusion Criteria for Participants with normal hepatic function: 1. Male or female participants, between 18 and 75 years of age, inclusive. 2. Body weight within 10% of the mean body weight of the participants with moderate HI, and BMI between 18.00 and 34.99 kg/m2, inclusive. 3. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). 4. Vital signs after 10 minutes resting in the supine position within the following range (or if out of range, considered NCS by the Investigator): 95 mmHg \< SBP \< 140 mmHg; 45 mmHg \< DBP \< 90 mmHg; 40 bpm \< HR \< 100 bpm. 5. 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances participants could have been enrolled with QTcF \> 450 ms. 6. Laboratory parameters within the normal range, unless the Investigator considered an abnormality to be clinically irrelevant for healthy participants, except in the case of platelets, white blood cells and hemoglobin below lower limit of normal (LLN). However serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase), total bilirubin (unless the participant has documented Gilbert's syndrome, with a maximum bilirubin level lower than 3 x upper limit of normal (ULN), and any parameter for which there was an explicit stopping rule could not exceed the upper laboratory range; renal function assessed using the eGFR calculated by the 2021 CKD-EPI formula had to be strictly above 60 mL/min/1.73m². 7. Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration. 8. Female participants of non-childbearing potential, defined as one of the following: 1. At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and FSH in the range for menopausal female confirmed by blood test according to current local standards at screening. 2. Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening. 9. Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to CTCG recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include: 1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal; 2. progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable; 3. intrauterine device (IUD); 4. intrauterine hormone-releasing system (IUS); 5. bilateral tubal occlusion; 6. vasectomized partner; 7. sexual abstinence (when in line with the preferred and usual subject's lifestyle). Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM were not acceptable methods of contraception. 10. Had given written informed consent prior to any procedure related to the study. 11. Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research. 12. Not under any administrative or legal supervision. 13. Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Maximum plasma concentration observed |
| AUClast of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Area under the plasma concentration versus time curve to the real time tlast |
| AUC0-inf of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Area under the plasma concentration versus time curve extrapolated to infinity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tmax of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Time to reach Cmax |
| t1/2 of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Apparent terminal half-life |
| CL/F of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Apparent total plasma clearance from plasma |
| Vz/F of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Apparent volume of distribution |
| Cmax of ITF2357 Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Maximum plasma concentration observed |
| AUClast of ITF2357 Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Area under the plasma concentration versus time curve to the real time tlast |
| AUC0-inf of ITF2357 Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Area under the plasma concentration versus time curve extrapolated to infinity |
| Tmax of ITF2357 Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Time to reach Cmax |
| t1/2 of ITF2357 Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Apparent terminal half-life |
| Fu of ITF2357 and Its Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available |
| AUC0-last,u of ITF2357 and Its Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound area under the plasma concentration versus time curve to the real time Tlast |
| AUC0-inf,u of ITF2357 and Its Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound area under the plasma concentration versus time extrapolated to infinity |
| Cmax,u of ITF2357 and Its Metabolites | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound maximum plasma concentration observed |
| CL/Fu of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound apparent total plasma clearance |
| Vz/Fu of ITF2357 | Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose | Unbound apparent volume of distribution |
| Incidence of Treatment Emergent Adverse Events (TEAEs) | From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. |
| Incidence of Treatment-Related TEAEs | From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one related TEAEs |
| Severity of Treatment Emergent Adverse Events (TEAEs) | From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event). |
| Incidence of TEAEs Leading to Withdrawal From the Study | From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one TEAE leading to withdrawal from the study |
| Incidence of Serious TEAEs (SAEs) | From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one Serious TEAE |
| Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality | From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates). |
| Incidence of Clinically Significant Vital Signs Abnormality | From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min). |
| Incidence of Clinically Significant Electrocardiogram Abnormality | From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec) |
| Incidence of Clinically Significant Physical Examination Abnormality | From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration) | Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement. |
Countries
Bulgaria, France
Participant flow
Recruitment details
A total of 24 participants, 8 participants in each group, were enrolled and completed the study.
Pre-assignment details
Thirty-one (31) participants were screened; 7 failed screening. In the NHF group, 4 did not meet criteria, 1 was eligible but not needed, and 1 withdrew consent. In the Mild HI group, 1 was eligible but not needed. All Moderate HI participants were included.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 38.6 year STANDARD_DEVIATION 13.09 |
| BMI BMI at D-1 | 27.273 kg/m2 STANDARD_DEVIATION 6.2001 |
| BMI BMI at screening | 26.835 kg/m2 STANDARD_DEVIATION 5.0353 |
| Child-Pugh score Child-Pugh score at D-1 | 7.38 Scores on a scale (5 to 15) STANDARD_DEVIATION 0.518 |
| Child-Pugh score Child-Pugh score at screening | 7.13 Scores on a scale (5 to 15) STANDARD_DEVIATION 0.354 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 21 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 4 Participants |
| Weight Weight at D-1 | 77.71 kg STANDARD_DEVIATION 22.502 |
| Weight Weight at screening | 78.63 kg STANDARD_DEVIATION 17.228 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 8 | 0 / 8 |
| other Total, other adverse events | 0 / 8 | 2 / 8 | 1 / 8 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 | 0 / 8 |
Outcome results
None listed